Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

(IPO Early Thoughts) CRCC High-Tech: Domestic Market Peaks, Exports Banned

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

CRCC High Tech Equipment Corp Ltd (H) / Equity Capital Markets

CRCC High Tech Equipment Corp Ltd (H) (1786 HK)

We have examined CRCC High-Tech's business fundamentals in our <a href="https://www.smartkarma.com/insights/ipo-early-thoughts-crcc-high-tech-domestic-market-peaks-exports-banned" target="_blank">IPO Early Thoughts</a>. The company recently launched its IPO to raise US$360-390m. <ul><li>In addition to what we have discussed earlier, we further highlight its under investment in the past, which is in strong contrast with its ambitious future plans</li><li>Growth expectation appears to be too high</li><li>Our Smartkarma framework rates the deal below borderline for participation </li></ul>More below the fold...

We have examined CRCC High-Tech's business fundamentals in our IPO Early Thoughts. The company recently launched its IPO to raise US$360-390m. In addition to what we have discussed earlier, we further highlight its under investment in the past, which is in strong contrast with its ambitious future plansGrowth expectation appears to be too highOur Smartkarma framework rates the deal below borderline for participation More below the fold...

China Railway Construction Corp (1186 HK)

CRCC High Tech Equipment Corp Ltd (H)

CRCC High-Tech IPO: A High Tech Irony